← Back to search
5nan

Crystal Structure of human IL-17AF in complex with human IL-17RA

Method: X-RAY DIFFRACTION Dmax: 130.5 Å Quality: GOOD
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Interleukin-17A

Homo sapiens

UniProt Q16552

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Other combination Heteromer Protein × 3 其他Polymer 1 PDB declaration: trimeric（3） Consistent with protein copy count Chain A； UniProt 24–155 Not recorded Interleukin-17 receptor A × 1 （Q96F46） Interleukin-17F × 1 （Q96PD4） 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-D-galactopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243
2 Protein heterocomplex Heteromer Protein × 3 PDB declaration: trimeric（3） Consistent with protein copy count Chain D； UniProt 24–155 Not recorded Interleukin-17 receptor A × 1 （Q96F46） Interleukin-17F × 1 （Q96PD4） NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 5NAN Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
2VXS Structure of IL-17A in complex with a potent, fully human neutralising antibody Deposited 2008-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 20–155（136 aa） Fragment：RESIDUES 20-155
Chain D 20–155（136 aa） Fragment：RESIDUES 20-155
Not recorded SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions 90.9 MM PCTP BUFFER PH 4.0, 9.1 MM PCTP BUFFER PH 9.5, 100 MM AMMONIUM SULPHATE, 14% W/V PEG3350
Resolution 2.63 Å R-free 0.264
2VXS Structure of IL-17A in complex with a potent, fully human neutralising antibody Deposited 2008-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 20–155（136 aa） Fragment：RESIDUES 20-155
Chain B 20–155（136 aa） Fragment：RESIDUES 20-155
Not recorded SO4 SULFATE ION × 8 X-RAY DIFFRACTION
X-ray crystallization conditions 90.9 MM PCTP BUFFER PH 4.0, 9.1 MM PCTP BUFFER PH 9.5, 100 MM AMMONIUM SULPHATE, 14% W/V PEG3350
Resolution 2.63 Å R-free 0.264
4HR9 Human interleukin 17A Deposited 2012-10-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Mutation：N45D, C106S Mutation：N45D, C106S No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.48 Å R-free 0.233
4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Mutation：N45D, C106S Mutation：N45D, C106S No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.15 Å R-free 0.232
4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain D 34–155（122 aa）
Chain E 34–155（122 aa）
Mutation：N45D, C106S Mutation：N45D, C106S NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.15 Å R-free 0.232
4QHU Crystal Structure of IL-17A/Fab6785 complex Deposited 2014-05-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 24–154（131 aa）
Chain D 24–154（131 aa）
Mutation：K70Q Mutation：K70Q GOL GLYCEROL × 5 CL CHLORIDE ION × 1 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.1 M sodium acetate, 12% PEG 5000, 0.2 M lithium sulfate, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.20 Å R-free 0.216
5HHV Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Deposited 2016-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain A 34–155（122 aa） Fragment：UNP residues 34-155
Chain B 34–155（122 aa） Fragment：UNP residues 34-155
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；.02 mM CdCl2, 0.02 M MgCl2, 0.02 M NiCl2, 0.1 M NaOAc pH=4.2-4.9, and 24-28 % PEG MME 2000
Resolution 2.20 Å R-free 0.236
5HHX Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Deposited 2016-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain A 18–155（138 aa） Fragment：UNP residues 20-155
Chain B 18–155（138 aa） Fragment：UNP residues 20-155
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.1 M NaOAc, pH=4.5 and 30% PEG MME 5000
Resolution 3.00 Å R-free 0.263
5HI3 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric
Chain A 24–155（132 aa） Fragment：UNP residues 24-155
Chain B 24–155（132 aa） Fragment：UNP residues 24-155
Not recorded 63O N-(4-{2-[({1-[2-(dimethylamino)-2-oxoethyl]cyclopentyl}acetyl)amino]ethyl}phenyl)-2-fluoro-Nalpha-[(1-methyl-1H-pyrazol-5-yl)carbonyl]-L-phenylalaninamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
Resolution 2.15 Å R-free 0.231
5HI4 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric
Chain A 24–155（132 aa） Fragment：UNP residues 24-155
Chain B 24–155（132 aa） Fragment：UNP residues 24-155
Not recorded 63P (9'S,17'R)-6'-chloro-N-methyl-9'-{[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino}-10',19'-dioxo-2'-oxa-11',18'-diazaspiro[cyclopentane-1,21'-tetracyclo[20.2.2.2~12,15~.1~3,7~]nonacosane]-1'(24'),3'(29'),4',6',12',14',22',25',27'-nonaene-17'-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
Resolution 1.80 Å R-free 0.224
5HI5 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric
Chain A 24–155（132 aa） Fragment：UNP residues 24-155
Chain B 24–155（132 aa） Fragment：UNP residues 24-155
Not recorded 63Q (4S,20R)-7-chloro-N-methyl-4-{[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino}-3,18-dioxo-2,19-diazatetracyclo[20.2.2.1~6,10~.1~11,15~]octacosa-1(24),6(28),7,9,11(27),12,14,22,25-nonaene-20-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
Resolution 1.80 Å R-free 0.219
5N7W Computationally designed functional antibody Deposited 2017-02-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain X 1–155（155 aa）
Chain Y 1–155（155 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；18% (w/v) PEG-MME 2000, 100mM PCTP pH4.5
Resolution 1.96 Å R-free 0.250
5N92 Crystal Structure of Human IL-17AF Deposited 2017-02-24 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 24–155（132 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；293 K；0.1M Bis-Tris-Propane, 0.5M Succinic acid, pH 7.0
Resolution 2.30 Å R-free 0.241
5VB9 IL-17A in complex with peptide Deposited 2017-03-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 38–155（118 aa） Fragment：UNP residues 38-155
Not recorded EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；281 K；Protein at 7.1 mg/ml in 10mM Bis-Tris pH 6.5, 10% glycerol, 150mM NaCl with 2 mM of peptide, equilibrated against a reservoir containing 20% PEG 3350 and 200mM Lithium Chloride.
Resolution 1.70 Å R-free 0.211
5VB9 IL-17A in complex with peptide Deposited 2017-03-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 38–155（118 aa） Fragment：UNP residues 38-155
Not recorded EDO 1,2-ETHANEDIOL × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；281 K；Protein at 7.1 mg/ml in 10mM Bis-Tris pH 6.5, 10% glycerol, 150mM NaCl with 2 mM of peptide, equilibrated against a reservoir containing 20% PEG 3350 and 200mM Lithium Chloride.
Resolution 1.70 Å R-free 0.211
6WIO Fab antigen complex Deposited 2020-04-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 1–155（155 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；294 K；20% PEG 3350 + 200mM Ammonium Chloride
Resolution 2.17 Å R-free 0.227
6WIR Fab antigen complex Deposited 2020-04-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 1–155（155 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；274 K；100mM Hepes pH 7, 15% PEG4K, 200mM Magnesium Chloride
Resolution 2.96 Å R-free 0.260
7AMA IL-17A in complex with small molecule modulators Deposited 2020-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 42–150（109 aa）
Chain B 42–150（109 aa）
Not recorded RMK ~{N}-[(2~{S})-1,1-dicyclopropyl-3-[[4-(3,5-dimethyl-1~{H}-pyrazol-4-yl)phenyl]amino]-3-oxidanylidene-propan-2-yl]-2-propan-2-yl-pyrazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10 000, isopropanol, sodium citrate
Resolution 2.48 Å R-free 0.255
7AMG IL-17A in complex with small molecule modulators Deposited 2020-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 42–150（109 aa）
Chain B 42–150（109 aa）
Not recorded RMQ (3~{R})-4-[4-[[(2~{S})-2-[[2,2-bis(fluoranyl)-2-phenyl-ethanoyl]amino]-3-(2-chlorophenyl)propanoyl]amino]phenyl]-3-[[(2~{S})-3-methyl-2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethanoylamino]butanoyl]amino]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10000, isopropanol, sodium citrate
Resolution 3.18 Å R-free 0.227
7AMG IL-17A in complex with small molecule modulators Deposited 2020-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 42–150（109 aa）
Chain D 42–150（109 aa）
Not recorded RMQ (3~{R})-4-[4-[[(2~{S})-2-[[2,2-bis(fluoranyl)-2-phenyl-ethanoyl]amino]-3-(2-chlorophenyl)propanoyl]amino]phenyl]-3-[[(2~{S})-3-methyl-2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethanoylamino]butanoyl]amino]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10000, isopropanol, sodium citrate
Resolution 3.18 Å R-free 0.227
7UWM Structure of the IL-17A-IL-17RA binary complex Deposited 2022-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 25–155（131 aa）
Chain B 25–155（131 aa）
Chain D 25–155（131 aa）
Chain E 25–155（131 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.50 Å
7UWN Structure of the IL-17A-IL-17RA-IL-17RC ternary complex Deposited 2022-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 7 PDB declaration: heptameric
Chain A 24–155（132 aa）
Chain B 24–155（132 aa）
Chain D 24–155（132 aa）
Chain E 24–155（132 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
7WKX IL-17A in complex with the humanized antibody HB0017 Deposited 2022-01-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain E 20–155（136 aa）
Chain F 20–155（136 aa）
Not recorded MLA MALONIC ACID × 7 ACY ACETIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；4% v/v Tacsimate pH 7.0, 12% w/v Polyethylene glycol 3,350
Resolution 2.81 Å R-free 0.254
7Z2M Crystal Structure of the 11.003 Fab in complex with human IL-17A Deposited 2022-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain J 34–155（122 aa）
Chain K 34–155（122 aa）
Not recorded GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2M sodium potassium tartrate, 20% (w/v) PEG 3,350
Resolution 1.90 Å R-free 0.227
7Z2M Crystal Structure of the 11.003 Fab in complex with human IL-17A Deposited 2022-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain G 34–155（122 aa）
Chain I 34–155（122 aa）
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2M sodium potassium tartrate, 20% (w/v) PEG 3,350
Resolution 1.90 Å R-free 0.227
7ZAN Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC Deposited 2022-03-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain A 34–155（122 aa） Fragment：IL-17A
Chain B 34–155（122 aa） Fragment：IL-17A
Mutation：N68D,C129S Mutation：N68D,C129S NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1M MES, 10.0% PEG DME 500
Resolution 5.06 Å R-free 0.353
8B7W Complex IL-17A/anti-IL-17A-76 Deposited 2022-10-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 34–155（122 aa）
Not recorded GOL GLYCEROL × 2 CL CHLORIDE ION × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；297 K；1.05 M NaCl, 7% v/v ethanol, 30% glycerol.
Resolution 2.85 Å R-free 0.265
8CDG Crystal structure of human IL-17A cytokine in complex with macrocycle Deposited 2023-01-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded UTF (9~{S},12~{R},19~{S})-9-[[4-[[(2~{S})-2-cyclohexyl-2-(2-phenylethanoylamino)ethanoyl]amino]phenyl]methyl]-12-methyl-7,10,13,21-tetrakis(oxidanylidene)-8,11,14,20-tetrazaspiro[4.17]docosane-19-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；100 mM sodium citrate buffer, pH 5.5, 8 % 2-propanol, and 10 % w/v PEG10k
Resolution 2.90 Å R-free 0.257
8DY1 Crystal Structure of scFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 35–155（121 aa）
Mutation：K93Q, C129S, A155Q SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.5；298 K；100 mM Tris, 200 mM LiSO4, 18% PEG 3350
Resolution 2.68 Å R-free 0.268
8DY1 Crystal Structure of scFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 35–155（121 aa）
Mutation：K93Q, C129S, A155Q SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.5；298 K；100 mM Tris, 200 mM LiSO4, 18% PEG 3350
Resolution 2.68 Å R-free 0.268
8DY5 Crystal Structure of spFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 35–155（121 aa）
Mutation：K93Q, C129S, A155Q CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；298 K；400 mM LiSO4, 15.5% PEG 3350
Resolution 2.20 Å R-free 0.232
8DY5 Crystal Structure of spFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 35–155（121 aa）
Mutation：K93Q, C129S, A155Q CA CALCIUM ION × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；298 K；400 mM LiSO4, 15.5% PEG 3350
Resolution 2.20 Å R-free 0.232
8DYF IL17A homodimer bound to Compound 10 Deposited 2022-08-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded U5I (5M)-3-[({2-[2-(2-{2-[2-({[(5M)-3-carboxy-5-(5,8-dihydroquinolin-4-yl)phenyl]amino}methyl)phenoxy]ethoxy}ethoxy)ethoxy]phenyl}methyl)amino]-5-(quinolin-4-yl)benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
Resolution 2.02 Å R-free 0.259
8DYG IL17A homodimer bound to Compound 7 Deposited 2022-08-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded U5Q (5P)-2-hydroxy-5-(6-methylquinolin-5-yl)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；290.15 K；1.6-2.0M Sodium Formate, 0.1M Tris, pH 7.8-8.8
Resolution 1.49 Å R-free 0.233
8DYH IL17A homodimer bound to Compound 6 Deposited 2022-08-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded U5X (5P)-N-benzyl-6-chloro-5-(quinolin-5-yl)pyridin-3-amine × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
Resolution 1.94 Å R-free 0.248
8DYI IL17A homodimer bound to Compound 5 Deposited 2022-08-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded U6C (5P)-5-[5-(benzylamino)pyridin-3-yl]-N-[2-(morpholin-4-yl)ethyl]-1H-indazol-3-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
Resolution 2.28 Å R-free 0.311
8USR IL17A homodimer complexed to Compound 23 Deposited 2023-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded XCE ~{N}-[(2~{S})-1-[[(1~{S})-1-(8~{a}~{H}-imidazo[1,2-a]pyrimidin-2-yl)ethyl]amino]-1-oxidanylidene-4-phenyl-butan-2-yl]-4,5-bis(chloranyl)-1~{H}-pyrrole-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；290 K；2 M NaCl, 0.1 M NaH2PO4, 0.1 M KH2PO4, 0.1 M MES pH 6.5
Resolution 1.83 Å R-free 0.250
8USR IL17A homodimer complexed to Compound 23 Deposited 2023-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 34–155（122 aa）
Chain D 34–155（122 aa）
Not recorded XCE ~{N}-[(2~{S})-1-[[(1~{S})-1-(8~{a}~{H}-imidazo[1,2-a]pyrimidin-2-yl)ethyl]amino]-1-oxidanylidene-4-phenyl-butan-2-yl]-4,5-bis(chloranyl)-1~{H}-pyrrole-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；290 K；2 M NaCl, 0.1 M NaH2PO4, 0.1 M KH2PO4, 0.1 M MES pH 6.5
Resolution 1.83 Å R-free 0.250
8USS IL17A complexed to Compound 7 Deposited 2023-10-29 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 34–155（122 aa）
Not recorded XCW 4,5-dichloro-N-[(1S)-1-cyclohexyl-2-{[(3S)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}-2-oxoethyl]-1H-pyrrole-2-carboxamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；15% w/v PEG 8K, 0.2 M MgCl2, 0.1 M Tris pH 8.5
Resolution 1.47 Å R-free 0.235
9FKX Crystal structure of IL-17A in complex with compound 18 Deposited 2024-06-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1IDT (4~{S})-1-[(~{R})-[2-[(~{S})-[4,4-bis(fluoranyl)cyclohexyl]-[[5-[1,1-bis(fluoranyl)ethyl]-1,3,4-oxadiazol-2-yl]amino]methyl]imidazo[1,2-b]pyridazin-7-yl]-cyclopropyl-methyl]-4-(trifluoromethyl)imidazolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1M citrate pH 5.5 10% PEG 10,000 12% isopropanol 10% ethylene glycol
Resolution 2.05 Å R-free 0.252
9FL3 Crystal structure of IL-17A in complex with compound 26 Deposited 2024-06-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1IDS (~{E})-~{N}-[(~{S})-[4,4-bis(fluoranyl)cyclohexyl]-[7-[(1~{S})-2-methoxy-1-[(4~{S})-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]ethyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1M citrate pH 5.5 10% PEG 10,000 12% isopropanol 10% ethylene glycol
Resolution 2.07 Å R-free 0.252
9H4D Crystal structure of IL-17A in complex with compound 18 Deposited 2024-10-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1ISH (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[(2-oxidanylidene-3H-benzimidazol-1-yl)methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1M citric acid pH 5.5 10% PEG 10000 12% iso-propanol 10% ethylene glycol
Resolution 2.12 Å R-free 0.241
9H4O Crystal structure of IL-17A in complex with compound 11 Deposited 2024-10-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded SO4 SULFATE ION × 5 A1ISG (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[[(4S)-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；293 K；0.1 M bis-tris pH 5.5 0.2 M lithium sulfate monohydrate 25% PEG 3350
Resolution 2.00 Å R-free 0.262
9H4O Crystal structure of IL-17A in complex with compound 11 Deposited 2024-10-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 34–155（122 aa）
Chain D 34–155（122 aa）
Not recorded SO4 SULFATE ION × 2 A1ISG (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[[(4S)-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；293 K；0.1 M bis-tris pH 5.5 0.2 M lithium sulfate monohydrate 25% PEG 3350
Resolution 2.00 Å R-free 0.262
9SFX Secukinumab Fv in complex with human IL-17A Deposited 2025-08-21 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain C 20–155（136 aa）
Not recorded GOL GLYCEROL × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；292 K；0.1M sodium acetate pH 4.6, 1.8M ammonium citrate dibasic
Resolution 2.60 Å R-free 0.213
9SG0 CJM112 Fv in complex with human IL-17A Deposited 2025-08-21 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 24–155（132 aa）
Not recorded SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1M MES pH 6.5, 0.2M ammonium sulfate, 15% PEG 5,000 MME
Resolution 2.65 Å R-free 0.256
9SG2 Ixekizumab Fab in complex with human IL-17A Deposited 2025-08-21 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 20–155（136 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.1M TRIS pH 8.5, 40% MPD
Resolution 2.92 Å R-free 0.246
9SGH Bimekizumab Fab in complex with human interleukin-17A Deposited 2025-08-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain I 34–155（122 aa）
Chain J 34–155（122 aa）
Mutation：C129S Mutation：C129S ZN ZINC ION × 6 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.2M zinc acetate, 0.1M imidazole pH 6.5, 10% PEG 8,000
Resolution 2.66 Å R-free 0.253
9SQI Crystal structure of IL-17A in complex with compound 21 Deposited 2025-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1JPQ ~{N}-[(~{S})-[3-[[(6~{R})-3-bromanyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M lithium sulfate 0.1M Bis-Tris pH 5.5 25% PEG 3,350
Resolution 1.48 Å R-free 0.226
9SQI Crystal structure of IL-17A in complex with compound 21 Deposited 2025-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 34–155（122 aa）
Chain D 34–155（122 aa）
Not recorded A1JPQ ~{N}-[(~{S})-[3-[[(6~{R})-3-bromanyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M lithium sulfate 0.1M Bis-Tris pH 5.5 25% PEG 3,350
Resolution 1.48 Å R-free 0.226
9SQX Crystal structure of IL-17A in complex with compound 19 Deposited 2025-09-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1JPS ~{N}-[(~{S})-cyclohexyl-[3-[(4-oxidanylidene-3~{H}-phthalazin-1-yl)methyl]-1~{H}-1,2,4-triazol-5-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2M lithium sulfate 0.1M Bis-Tris pH 5.5 25% PEG 3,350
Resolution 1.41 Å R-free 0.227
9SQX Crystal structure of IL-17A in complex with compound 19 Deposited 2025-09-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 34–155（122 aa）
Chain D 34–155（122 aa）
Not recorded A1JPS ~{N}-[(~{S})-cyclohexyl-[3-[(4-oxidanylidene-3~{H}-phthalazin-1-yl)methyl]-1~{H}-1,2,4-triazol-5-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2M lithium sulfate 0.1M Bis-Tris pH 5.5 25% PEG 3,350
Resolution 1.41 Å R-free 0.227
9SR8 Crystal structure of IL-17A in complex with compound 22 Deposited 2025-09-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 34–155（122 aa）
Chain B 34–155（122 aa）
Not recorded A1JPU ~{N}-[(~{S})-[3-[[7-bromanyl-3-methyl-2,4-bis(oxidanylidene)quinazolin-1-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1M citrate pH 5.5 10% PEG 10,000 12% isopropanol 10% ethylene glycol
Resolution 2.56 Å R-free 0.254
9YIC Crystal structure of human IL-17A in complex with Compound 1 Deposited 2025-10-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 35–155（121 aa）
Chain B 35–155（121 aa）
Not recorded A1CXF (3S)-N-[(3-{[(1S)-2-anilino-1-cyclohexyl-2-oxoethyl]carbamoyl}phenyl)methyl]-2,2-dimethylthiomorpholine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；295.15 K；13.7% PEG 6000, 0.1M sodium malonate pH 4.0, 1.3% methyl-2,4-pentanediol
Resolution 3.15 Å R-free 0.242
9YIC Crystal structure of human IL-17A in complex with Compound 1 Deposited 2025-10-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 35–155（121 aa）
Chain D 35–155（121 aa）
Not recorded A1CXF (3S)-N-[(3-{[(1S)-2-anilino-1-cyclohexyl-2-oxoethyl]carbamoyl}phenyl)methyl]-2,2-dimethylthiomorpholine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；295.15 K；13.7% PEG 6000, 0.1M sodium malonate pH 4.0, 1.3% methyl-2,4-pentanediol
Resolution 3.15 Å R-free 0.242

43 other PDB entries and 55 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name IL17_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–132； UniProt 24–155 Author chain D； PDBConstruct 1–132； UniProt 24–155

Interleukin-17 receptor A

Homo sapiens

UniProt Q96F46

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Other combination Heteromer Protein × 3 其他Polymer 1 PDB declaration: trimeric（3） Consistent with protein copy count Chain B； UniProt 33–320 Not recorded Interleukin-17A × 1 （Q16552） Interleukin-17F × 1 （Q96PD4） 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-D-galactopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243
2 Protein heterocomplex Heteromer Protein × 3 PDB declaration: trimeric（3） Consistent with protein copy count Chain C； UniProt 33–320 Not recorded Interleukin-17A × 1 （Q16552） Interleukin-17F × 1 （Q96PD4） NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 5NAN Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
3JVF Crystal structure of an Interleukin-17 receptor complex Deposited 2009-09-16 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 32–317（286 aa） Fragment：extracellular domain
Non-standard monomer：Yes (specific site not provided by mmCIF) CA CALCIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 9.2；295 K；PEG6000, 0.1M CAPSO, calcium chloride, pH 9.2, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 3.30 Å R-free 0.256
4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 32–317（286 aa）
Mutation：N175D, N234D No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.15 Å R-free 0.232
4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain F 32–317（286 aa）
Mutation：N175D, N234D NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.15 Å R-free 0.232
4NUX Structure of receptor A Deposited 2013-12-04 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–591（216 aa） Fragment：SEFIR domain (UNP residues 376-591)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；293 K；0.1M MES, 5%PEG6000, pH 6.0, EVAPORATION, temperature 293K
Resolution 2.29 Å R-free 0.242
5N9B Crystal Structure of unliganded human IL-17RA Deposited 2017-02-24 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 33–318（286 aa） Fragment：Extracellular domain, UNP rsidues 33-318
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；293 K；Tris-HCl, PEG 2000 MME, lithium sulfate
Resolution 1.90 Å R-free 0.234
7UWL Structure of the IL-25-IL-17RB-IL-17RA ternary complex Deposited 2022-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain E 33–317（285 aa）
Chain F 33–317（285 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 14 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
7UWM Structure of the IL-17A-IL-17RA binary complex Deposited 2022-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 33–304（272 aa）
Chain F 33–304（272 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.50 Å
7UWN Structure of the IL-17A-IL-17RA-IL-17RC ternary complex Deposited 2022-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 7 PDB declaration: heptameric
Chain C 33–317（285 aa）
Chain F 33–317（285 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
7ZAN Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC Deposited 2022-03-22 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain C 33–320（288 aa）
Mutation：N49D, N206D, N265D NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1M MES, 10.0% PEG DME 500
Resolution 5.06 Å R-free 0.353
9OT1 Helical assembly of the IL-17RA/RB/ACT1 complex Deposited 2025-05-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 19 PDB declaration: 19-meric
Chain A 361–866（506 aa）
Chain B 361–866（506 aa）
Chain C 361–866（506 aa）
Chain D 361–866（506 aa）
Not recorded ZN ZINC ION × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen NITROGEN
Resolution 3.00 Å

9 other PDB entries and 10 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name I17RA_HUMAN
Isoform —
PDB entities 2
Chains and sequence ranges Author chain B； PDBConstruct 1–288； UniProt 33–320 Author chain C； PDBConstruct 1–288； UniProt 33–320

Interleukin-17F

Homo sapiens

UniProt Q96PD4

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Other combination Heteromer Protein × 3 其他Polymer 1 PDB declaration: trimeric（3） Consistent with protein copy count Chain F； UniProt 31–163 Not recorded Interleukin-17A × 1 （Q16552） Interleukin-17 receptor A × 1 （Q96F46） 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-D-galactopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243
2 Protein heterocomplex Heteromer Protein × 3 PDB declaration: trimeric（3） Consistent with protein copy count Chain E； UniProt 31–163 Not recorded Interleukin-17A × 1 （Q16552） Interleukin-17 receptor A × 1 （Q96F46） NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate Resolution 3.30 Å R-free 0.243

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 5NAN Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
3JVF Crystal structure of an Interleukin-17 receptor complex Deposited 2009-09-16 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 31–163（133 aa）
Chain B 31–163（133 aa）
Not recorded CA CALCIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 9.2；295 K；PEG6000, 0.1M CAPSO, calcium chloride, pH 9.2, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 3.30 Å R-free 0.256
5N92 Crystal Structure of Human IL-17AF Deposited 2017-02-24 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 31–163（133 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；293 K；0.1M Bis-Tris-Propane, 0.5M Succinic acid, pH 7.0
Resolution 2.30 Å R-free 0.241
6HG4 Crystal Structure of the human IL-17RC ECD in complex with human IL-17F Deposited 2018-08-22 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 31–163（133 aa） Fragment：IL-17F
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；200mM ammonium citrate tribasic, 20.0% PEG 3350
Resolution 3.32 Å R-free 0.239
6HG9 Crystal Structure of the human IL-17RC ECD in complex with human IL-17F, Crystal form II Deposited 2018-08-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 31–163（133 aa） Fragment：IL-17F
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；200mM ammonium formate, 20.0% PEG 3350
Resolution 3.62 Å R-free 0.258
6HGO Crystal Structure of human IL-17F Deposited 2018-08-23 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–163（133 aa） Fragment：IL-17F
Chain B 31–163（133 aa） Fragment：IL-17F
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；200mM ammonium sulfate, 20.0% PEG 3350
Resolution 2.10 Å R-free 0.220
6HGO Crystal Structure of human IL-17F Deposited 2018-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 31–163（133 aa） Fragment：IL-17F
Chain D 31–163（133 aa） Fragment：IL-17F
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；200mM ammonium sulfate, 20.0% PEG 3350
Resolution 2.10 Å R-free 0.220
6PPG Crystal structure of IL17FF bound to Fab fragments of MCAF5352A Deposited 2019-07-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain F 31–163（133 aa）
Chain G 31–163（133 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 CD CADMIUM ION × 53 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；292 K；0.1M sodium acetate pH 4.6, 0.1M cadmium chloride, 30% PEG400
Resolution 2.75 Å R-free 0.275
8RUU Fabs derived from bimekizumab in complex with IL-17F Deposited 2024-01-31 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain X 31–163（133 aa）
Chain Y 31–163（133 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292 K；PEG 8000, lithium sulphate, glycerol
Resolution 2.81 Å R-free 0.241

7 other PDB entries and 8 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name IL17F_HUMAN
Isoform —
PDB entities 3
Chains and sequence ranges Author chain E； PDBConstruct 7–139； UniProt 31–163 Author chain F； PDBConstruct 7–139； UniProt 31–163

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 5nan

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 5nan
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id5nan
Deposition date deposition_date2017-02-28
Structure title titleCrystal Structure of human IL-17AF in complex with human IL-17RA
Keywords keywordsCystine-knot, Fibronectin type III, cytokine; CYTOKINE
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier40.45 Å
Radius of gyration Rg (electron density) rg_electron40.01 Å
Forward intensity I(0) i0209233000.00
Molecular weight molecular_weight112960.0 kDa
Excluded volume excluded_volume139400 ų
Envelope volume envelope_volume200720 ų
Hydration-shell volume shell_volume41821 ų
Envelope diameter envelope_diameter131.1 Å
Shell Rg shell_rg45.89 Å
Envelope Rg envelope_rg38.97 Å
Shape Rg shape_rg39.99 Å
Total Rg total_rg40.41 Å
Total atoms total_atoms7923
Residues n_residues972
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax130.5 Å
Rg (real space) rg_real40.50 Å
Rg uncertainty (real space) rg_real_error1.09 Å
I(0) (real space) i0_real2.0920e+08
I(0) uncertainty (real space) i0_real_error3.7460e+06
Rg (reciprocal space) rg_reciprocal40.45 Å
I(0) (reciprocal space) i0_reciprocal209200000.0000
Solution quality estimate total_estimate0.8739
Solution quality rating solution_quality GOOD a GOOD solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary33.5 Å
Skewness Skewness skewness0.197
Kurtosis Kurtosis kurtosis-0.859
Angular range angular_range— – 0.1950 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha16880000.0000
Real-space data points n_real_points40
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.874; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.856; Smooth: 0.878
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (5)

▼

7. Fold Classification (SCOP + CATH) 8 domains

CATH v4.4 (8 domains)

Domain ID domain_id5nanA01
Class class2 — Mainly Beta
Architecture architecture10 — Ribbon
Topology topology90 — Cystine Knot Cytokines, subunit B
Homologous superfamily homologous superfamily10 — Cystine-knot cytokines
Domain ID domain_id5nanB01
Class class2 — Mainly Beta
Architecture architecture60 — Sandwich
Topology topology40 — Immunoglobulin-like
Homologous superfamily homologous superfamily2160 — Interleukin-17 receptor A/B, fibronectin-III-like domain 1
Domain ID domain_id5nanB02
Class class2 — Mainly Beta
Architecture architecture60 — Sandwich
Topology topology40 — Immunoglobulin-like
Homologous superfamily homologous superfamily2150 — Interleukin-17 receptor A/B, fibronectin-III-like domain 2
Domain ID domain_id5nanC01
Class class2 — Mainly Beta
Architecture architecture60 — Sandwich
Topology topology40 — Immunoglobulin-like
Homologous superfamily homologous superfamily2160 — Interleukin-17 receptor A/B, fibronectin-III-like domain 1
Domain ID domain_id5nanC02
Class class2 — Mainly Beta
Architecture architecture60 — Sandwich
Topology topology40 — Immunoglobulin-like
Homologous superfamily homologous superfamily2150 — Interleukin-17 receptor A/B, fibronectin-III-like domain 2
Domain ID domain_id5nanD01
Class class2 — Mainly Beta
Architecture architecture10 — Ribbon
Topology topology90 — Cystine Knot Cytokines, subunit B
Homologous superfamily homologous superfamily10 — Cystine-knot cytokines
Domain ID domain_id5nanE00
Class class2 — Mainly Beta
Architecture architecture10 — Ribbon
Topology topology90 — Cystine Knot Cytokines, subunit B
Homologous superfamily homologous superfamily10 — Cystine-knot cytokines
Domain ID domain_id5nanF00
Class class2 — Mainly Beta
Architecture architecture10 — Ribbon
Topology topology90 — Cystine Knot Cytokines, subunit B
Homologous superfamily homologous superfamily10 — Cystine-knot cytokines
▶

8. Citations (1)

▶

9. Files and Curves (10)